Also found in: Medical, Wikipedia.


A thiazolidinedione drug, C19H20N2O3S, used in its hydrochloride form to treat type 2 diabetes.

[pio-, origin unknown + -glitazone, thiazolidinedione suff.; see rosiglitazone.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n pioglitazona
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
A NASH TAG presentation in January 2019 highlighted data in which PXL065 was observed to have a more favorable profile versus pioglitazone and other thiazolidinediones (TZDs).
Pioglitazone, a derivative of thiazolidinedione, is a PPARI3 agonist used in the treatment of individuals with type 2 diabetes (Kota et al., 2005).
It adds, "Because some NASH patients are treated with vitamin E or pioglitazone, enrollment of such patients in clinical trials may confound treatment effects.
Poxel, a biopharmaceutical company, has commenced part two of the phase 1a study for PXL065, a deuterium-stabilised R-stereoisomer of pioglitazone intended for the treatment of non-alcoholic steatohepatitis (NASH), it was reported yesterday.
The remaining two were used as interventional groups and received either pioglitazone or aliskerin for four weeks after induction of diabetes.
PIOGLITAZONE THERAPY given for 18 months benefited patients with nonalcoholic steatohepatitis (NASH) similarly regardless of whether they had type 2 diabetes mellitus or prediabetes, according to the results of a randomized prospective trial.
Pioglitazone, which works on reversing almost all mechanisms involved in the pathogenesis, is the new suggested preventive option in this study.
Pioglitazone is a special ligand of peroxisome proliferators-activated receptor-[gamma] (PPAR-[gamma]).
PPAR-[gamma] agonist- (pioglitazone) attenuated upper airway allergic inflammation may be mediated by the induction of Tregs [14].
Moreover, preclinical studies conducted both in vitro and in vivo have provided the evidence of anticancer properties of particular PPAR-[gamma] agonists, rosiglitazone and pioglitazone. Several studies demonstrating rosiglitazone and pioglitazone on Pomc suppression have been done [12, 18, 19], and an opposite effect of rosiglitazone was also shown by Kreutzer et al.
Previous studies have shown that several drugs, including metformin, rosiglitazone, and pioglitazone, can control high blood glucose levels and protect patients from diabetes-related complications [3].
Objective: To determine the effect of pioglitazone on cardiometabolic risk factors in non-diabetic patients with dyslipidaemia.